These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 29615460)

  • 21. [Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].
    Xiao Y; Zhu X; Gu Y; Chen S; Liang L; Cao B
    Zhongguo Fei Ai Za Zhi; 2018 Mar; 21(3):241-250. PubMed ID: 29587953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
    Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
    PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
    Singh A; Daemen A; Nickles D; Jeon SM; Foreman O; Sudini K; Gnad F; Lajoie S; Gour N; Mitzner W; Chatterjee S; Choi EJ; Ravishankar B; Rappaport A; Patil N; McCleland M; Johnson L; Acquaah-Mensah G; Gabrielson E; Biswal S; Hatzivassiliou G
    Clin Cancer Res; 2021 Feb; 27(3):877-888. PubMed ID: 33077574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
    Di Federico A; De Giglio A; Parisi C; Gelsomino F
    Eur J Cancer; 2021 Nov; 157():108-113. PubMed ID: 34500370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
    Scheffler M; Holzem A; Kron A; Nogova L; Ihle MA; von Levetzow C; Fassunke J; Wömpner C; Bitter E; Koleczko S; Abdulla DSY; Michels S; Fischer R; Riedel R; Weber JP; Westphal T; Gerigk U; Kern J; Kaminsky B; Randerath W; Kambartel KO; Merkelbach-Bruse S; Büttner R; Wolf J
    Lung Cancer; 2020 Jun; 144():40-48. PubMed ID: 32361034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?
    Dempke WCM; Reck M
    Lung Cancer; 2021 Sep; 159():10-17. PubMed ID: 34303275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
    Shang X; Li Z; Sun J; Zhao C; Lin J; Wang H
    Lung Cancer; 2021 Apr; 154():105-112. PubMed ID: 33640623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Transcriptomic Approach Outperforms Mutational Analysis to Identify KEAP1/NFE2L2 Pathway Activation in Patients With NSCLC.
    Hijazo-Pechero S; Muñoz-Pinedo C; Nadal E
    J Thorac Oncol; 2023 Nov; 18(11):1431-1433. PubMed ID: 37879763
    [No Abstract]   [Full Text] [Related]  

  • 29. KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub.
    Scalera S; Mazzotta M; Cortile C; Krasniqi E; De Maria R; Cappuzzo F; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2022 Jun; 17(6):751-757. PubMed ID: 35351670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis.
    Zhang C; Zhang C; Li J; Wang H
    J Thorac Oncol; 2020 Jun; 15(6):e85-e86. PubMed ID: 32471565
    [No Abstract]   [Full Text] [Related]  

  • 31. Co-occurring KEAP1 and TP53 mutations in lung squamous cell carcinoma induced primary resistance to thoracic radiotherapy: A case report.
    Nishimura R; Yoshida T; Torasawa M; Kashihara T; Ohe Y
    Thorac Cancer; 2023 Jan; 14(2):206-209. PubMed ID: 36453575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
    Scheffler M; Ihle MA; Hein R; Merkelbach-Bruse S; Scheel AH; Siemanowski J; Brägelmann J; Kron A; Abedpour N; Ueckeroth F; Schüller M; Koleczko S; Michels S; Fassunke J; Pasternack H; Heydt C; Serke M; Fischer R; Schulte W; Gerigk U; Nogova L; Ko YD; Abdulla DSY; Riedel R; Kambartel KO; Lorenz J; Sauerland I; Randerath W; Kaminsky B; Hagmeyer L; Grohé C; Eisert A; Frank R; Gogl L; Schaepers C; Holzem A; Hellmich M; Thomas RK; Peifer M; Sos ML; Büttner R; Wolf J
    J Thorac Oncol; 2019 Apr; 14(4):606-616. PubMed ID: 30605727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C.
    Boeschen M; Kuhn CK; Wirtz H; Seyfarth HJ; Frille A; Lordick F; Hacker UT; Obeck U; Stiller M; Bläker H; von Laffert M
    Lung Cancer; 2023 Oct; 184():107361. PubMed ID: 37699269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes.
    Liu Z; Deng M; Wu L; Zhang S
    Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
    Vokes NI; Chambers E; Nguyen T; Coolidge A; Lydon CA; Le X; Sholl L; Heymach JV; Nishino M; Van Allen EM; Jänne PA
    J Thorac Oncol; 2022 Jun; 17(6):779-792. PubMed ID: 35331964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
    Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
    J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
    Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
    Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Keap1 Inhibits Metastatic Properties of NSCLC Cells by Stabilizing Architectures of F-Actin and Focal Adhesions.
    Wu B; Yang S; Sun H; Sun T; Ji F; Wang Y; Xu L; Zhou D
    Mol Cancer Res; 2018 Mar; 16(3):508-516. PubMed ID: 29330291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas.
    Jin X; Zheng Y; Chen Z; Wang F; Bi G; Li M; Liang J; Sui Q; Bian Y; Hu Z; Qiao Y; Xu S
    Cancer Med; 2021 Dec; 10(23):8673-8692. PubMed ID: 34617407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.